Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma
- 1 August 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Oncology
- Vol. 7 (4), 276-284
- https://doi.org/10.1007/s11864-006-0037-2
Abstract
Immunomodulatory agents, including cytokines, monoclonal antibodies, and CpG oligonucleotides, have properties that suggest they have the ability to augment rituximab in the treatment of non-Hodgkin's lymphoma. Although several clinical trials have promising results, no randomized trials of reasonable size have been performed to date, limiting the ability to discern whether combinations of immunomodulatory agents with rituximab impact clinical outcome. Until such trials are mature, we do not recommend using these agents in combination outside of the research setting.Keywords
This publication has 40 references indexed in Scilit:
- Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic interventionOncogene, 2005
- Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an ExampleHematology-American Society Hematology Education Program, 2005
- Developing New Monoclonal Antibodies for Aggressive LymphomaClinical Cancer Research, 2004
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyThe Journal of Experimental Medicine, 2004
- Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s LymphomaClinical Cancer Research, 2004
- Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleBlood, 2004
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-α2a and granulocyte-macrophage colony stimulating factorSeminars in Oncology, 2002
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002